Bruker cut its FY2025 adjusted EPS guidance from $2.40-$2.48 to $1.95-$2.05 and also lowered FY2025 sales guidance from $3.480 billion-$3.550 billion to $3.430 billion-$3.500 billion. Frank H. Laukien, Bruker's President and CEO, said, "Life-science research instruments demand is under pressure at the moment. Our second quarter came in below expectations, as we experienced challenging demand conditions in the US academic market, as well as in biopharma and industrial markets. Tariffs and a stiff currency he ...